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Background: The postnasal drip (PND) syndrome is often linked as a cause of chronic cough
although this is disputed.
Objectives: We examined the effect of specific topical treatment of rhinosinusitis on cough in
patients presenting with a chronic cough associated with a postnasal drip or ‘nasal catarrh’.
Methods: Patients presenting with a chronic cough and who complained of PND were enrolled
and symptoms of PND and cough were assessed by questionnaire and by a capsaicin cough
response. Rhinosinusitis was assessed by questionnaires, direct examination of the nose and
by high-resolution computed tomography. In an open study, they were treated with fluticasone
nasules, ipratropium bromide and azelastine nasal sprays for 28 days, after which they were
re-assessed.
Results: Eighteen out of 21 patients completed the study. All patients reported having the
presence of mucus in the throat. Mean cough score improved post-treatment (p< 0.05), but
there was no significant change in capsaicin cough sensitivity or nasal catarrh questionnaire
score. There was improvement in anterior nasal discharge symptom scores (pZ 0.005) and
in endoscopic nasal scores post-treatment (p< 0.01), with a tendency to improved PND scores.
Conclusion: In a pilot open ‘real-life’ study treatment targeted towards rhinosinusitis accom-
panying PND syndrome and chronic cough led to an improvement in cough. A randomised
controlled study is now needed to confirm or refute these findings.
ª 2009 Published by Elsevier Ltd.rt & Lung Institute, Imperial
LY, UK.
ac.uk (K.F. Chung).
9 Published by Elsevier Ltd.Introduction
Chronic cough is a common problem often resulting in
referral to secondary care.1 Postnasal drip (PND) syndrome
is frequently cited as a common cause of chronic cough, as
shown in a series of earlier publications from the US.2e6
Postnasal drip and cough 1701PND refers to the sensation of nasal secretions at the back
of the throat (or of a ‘drip’), often resulting in the need to
clear the throat and is associated with nasal stuffiness or
nasal discharge. Sometimes, the patient may describe the
sensation of ‘something running down the back of the
throat’. It is also often referred to as ‘nasal catarrh’ or
‘mucus in the throat’ by patients in the UK. The diagnosis of
PND-induced cough is made by reviewing symptoms, phys-
ical examination, radiological findings and response to
therapy.7 There are numerous rhinological conditions that
can give rise to a PND including allergic, non-allergic and
infective rhinosinusitis.
There has been some dispute as to whether the PND
syndrome is indeed a syndrome, and whether this can cause
chronic cough.8 The relationship between PND and cough is
often disputed.9 Thus, it has been argued that gastro-
oesophageal reflux may sometimes be the cause of the
symptoms associated with PND.10 However, patients with
PND syndrome often have features of rhinosinusitis, and it is
therefore not implausible that this may be involved in
causing nasal secretions at the back of the throat, leading to
cough. The reasons why the dispute about PND and cough
continues include the fact that previous studies on PNDS
have not examined the link between abnormalities of the
nose and sinuses with chronic cough, have not quantified the
symptoms associated with PND and have not recorded
the effect of treatment given specifically and topically to the
nose and sinuses in these patients on chronic cough and
the nasal mucosa.
Our own experience in the Cough clinic and Nose clinic
at the Royal Brompton Hospital, London, UK, relating to the
success of controlling cough by treating rhinosinusitis has
been very variable. In addition, in our cohort of chronic
cough patients, a smaller proportion were labelled as
having the PND syndrome as causing their cough,11
compared to earlier studies.2e6 We have examined in a pilot
study the relationship between PND syndrome and cough by
recruiting patients presenting with chronic cough and who
also complained of PND, described as mucus in the back of
the throat or as nasal catarrh, and observing the effects of
local specific treatments applied to the nose and sinuses on
the cough.
Methods
Study population
This study was designed as an open real-life study. Patients,
aged between 18 and 75 years, were recruited from our
cough clinic over a period of 6 months. All subjects had
a persistent dry cough of at least 8 weeks’ duration and
experienced and reported the sensation of ‘mucus in the
throat’. They had been investigated and treated with
a standard protocol for the exclusion of asthma and gas-
trooesophageal reflux. Subjects who did not report ‘mucus
in the throat’ were excluded, and none of the subjects
were on treatment for rhinosinusitis at the time of inclusion
into the study. Other exclusion criteria included bronchi-
ectasis, chronic obstructive pulmonary disease (COPD),
current smokers, glaucoma, history of hypersensitivity to
any of the study medications and those on prolongedcourses of oral or injectable corticosteroids. The study was
approved by the Brompton, Harefield and National Heart
and Lung Institute Research Ethics Committee, and all
subjects gave informed consent to participate.
Study protocol
There were five study visits. At the first visit, subjects had
skin prick tests to common aeroallergens, lung function
tests and exhaled nitric oxide measurements. They
completed Nasal Catarrh and Leicester Cough Question-
naires. They were asked to complete diary cards doc-
umenting the severity of their cough and nasal symptoms
for two weeks prior to commencing the study medications.
They underwent an ear, nose and throat (ENT) assessment
and had a high resolution computed tomography (HRCT)
scan of the nose and paranasal sinuses at Visit 2.
At the third visit, their pre-treatment diary cards were
collected, and they were issued with diary cards for four
weeks. The subjects had a capsaicin cough challenge and
commenced their four-week treatment, consisting of
topical nasal sprays of fluticasone nasules (400 mg once
a day), ipratropium nasal spray (42 mg three times a day)
and azelastine nasal spray (140 mg twice daily). The
patients were reviewed at the end of the treatment period
at Visit 4, when they completed nasal catarrh and Leicester
Cough Questionnaires, and had repeat spirometric tests,
exhaled nitric oxide measurements and a capsaicin cough
challenge. Diary cards were collected. The final visit con-
sisted of an ENT review and a nasal examination.
Questionnaires and diary cards
The Leicester Cough Questionnaire was used to assess the
impact of chronic cough on the patients’ quality of life.12
The severity of cough symptoms was also assessed using
a previously described cough symptom score.13 Subjects
completed daily diary cards on their cough and nasal
symptoms for two weeks before the study treatment
commenced and throughout the four-week treatment
period. The mean daily score pre- and post-treatment was
calculated. Cough symptoms were graded 0e5 (0Z no
cough; 1Z cough for short period; 2Z cough for than 2
short periods; 3Z frequent coughing does not interfere
with activities; 4Z frequent coughing interferes with
activities; 5Z distressing cough most of the day). The
presence/severity of an anterior nasal discharge and
‘mucous in the back of the throat’ were graded 0e3
(0Z none; 1Zmild; 2Zmoderate; 3Z severe). The nasal
catarrh questionnaire had 12 questions on nasal symptoms
and was marked out of 24 with the higher the score, the
more severe the symptoms.14
Spirometry and exhaled nitric oxide
Forced expiratory volume in 1 s (FEV1) and forced vital
capacity (FVC) was measured using a dry wedge spirometer
(Vitalograph, Buckingham, UK).
Exhaled nitric oxide was measured using a Niox analyser
(Aerocrine, Stockholm, Sweden) at a constant expiratory
flow rate (0.05 L s1).
1702 P. Macedo et al.Capsaicin cough challenge
Capsaicin cough challenge was performed as previously
described.15 Briefly, single-breath inhalations of sodium
chloride (0.9%) and increasing doubling concentrations of
capsaicin (0.977e500 mmol/L) from a breath-activated
dosimeter were inhaled in succession. Coughs were counted
for 1 min after each dose. The end-point was the concen-
tration of capsaicin required to induce five coughs (C5), and
the data was analysed as the log10 C5.
ENT review
Patients attended the Nose clinic at the Royal Brompton
Hospital. The postnasal space and pharynx was examined
via nasal endoscopy, and the degree of rhinosinusitis scored
(SD, IM & HS). The HRCT scan of the nose and sinuses was
scored using the modified LundeMacKay grading system.16
Data analysis
Data are reported as mean SEM. Statistical analyses were
performed using GraphPad Prism 4. The Wilcoxon signed-
rank test was used to analyse the difference between pre-
and post-treatment symptom scores, endoscopic nasal
scores and capsaicin cough challenge.
Results
Of the 21 patients enrolled, 18 (14 of female gender)
completed the study. One subject was diagnosed with
glaucoma after consenting to participate and was with-
drawn prior to commencing treatment, the other two
withdrew prior to visit 2. The mean age was 57 years (range
44e75). Four out of 18 subjects were atopic as assessed by
one or more positive skin prick tests to common aero-
allergens. All subjects had normal lung function (mean FEV1
was 92% 3.4% predicted) and their mean exhaled nitric
oxide was 13 1.3 ppb. Although all subjects reported
having ‘mucous in the back of the throat’, a third of them
had not heard the term PND prior to the study.
The patients had a mean cough score of 3.19 0.34 prior
to starting treatment, and a mean LCQ score of 11.4 1.01.
The capsaicin log C5 concentration was 0.425 0.11. The
subjects’ mean anterior nasal discharge symptom scorePre Post
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Figure 1 Self-administered cough score and nasal catarrh que
rhinosinusitis.1.75 0.20 and posterior nasal discharge score of
2.01 0.14.
At nasal endoscopy before starting treatment, 80% of
subjects had a nasal discharge and a third had mucosal
oedema. Twenty-seven percent of patients had crusting,
and a third had a deviated septum. Six percent had nasal
polyps. Eight out of 18 subjects had normal (clear) CT scans
of their nose and sinuses, 8 had mucosal thickening in at
least 1 sinus and 2 had at least one opacified sinus.
All patients reported taking their three topical treat-
ments regularly and none reported any adverse events. At
the end of the treatment period, five out of 18 patients
reported a significant improvement in their cough symp-
toms. Two of the three patients without clinical evidence of
PND at the time of examination reported an improvement
in their cough after the treatment period.
There was a significant decrease in mean cough severity
score post-treatment (Fig. 1) but no significant change in
LCQ score overall (Fig. 2). There were no significant
changes in exhaled nitric oxide, lung function or capsaicin
cough sensitivity post-treatment (Fig. 3).
There was also no significant change in nasal catarrh
questionnaire scores (Fig. 1) and in PND symptom scores
(pZ 0.09) (Fig. 3). However, there was a significant clinical
improvement in anterior nasal discharge symptom scores
(Fig. 3), accompanied by a significant improvement in
endoscopic nasal scores post-treatment (Fig. 4), charac-
terised by reduction in discharge and oedema.
There was a significant correlation (pZ 0.002) between
baseline LCQ score and baseline mean cough score (Fig. 5).
There was no correlation between LCQ score and capsaicin
C5, or between change in cough severity score and change
in anterior or posterior nasal discharge scores.
Discussion
In this pilot study, we examined the effect of topical
treatments for rhinosinusitis on the symptoms of postnasal
drip and accompanying chronic cough in a cohort of
patients with chronic cough as their main symptom. The
treatments used were topical corticosteroids, and nasal
applications of H2-antihistamines and anticholinergic nasal
spray. No antibiotics or saline sprays were given. Overall,
treatment was associated with a significant improvement in
cough scores post-treatment that accompanied reductions
in symptom scores for anterior nasal discharge, a non-Pre Post
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Figure 2 Individual values for exhaled nitric oxide (panel A), lung function as FEV1% predicted (Panel B), Leicester cough
questionnaire score (Panel C) and capsaicin cough sensitivity as log C5 (Panel D) before (pre) and after (post) treatment of rhi-
nosinusitis. None of the parameters shows significant changes.
Postnasal drip and cough 1703significant reduction for postnasal discharge, and no
changes in the nasal catarrh questionnaire, although direct
inspection of the nasal passages showed improvement in
the appearances of the nasal mucosa. We observed no
significant changes in capsaicin cough sensitivity or the
Leicester Cough questionnaire. Our data suggest that
treating PND syndrome with a combination of topical
corticosteroids, antihistamines and anticholinergic lead to
a modest improvement in chronic cough although this
requires confirmation in a randomised controlled study. At
the end of our study, 28% of patients had reported an
overall improvement in their cough scores following treat-
ment but with no improvement in LCQ scores or capsaicin
cough responses. In other studies of chronic cough, topicalP
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Figure 3 Symptom scores for anterior and for posterior nasal disc
There was significant improvement in anterior nasal discharge sc
changed (pZ 0.009).corticosteroids used as treatment of the primary condition
associated with cough such as cough variant asthma or
eosinophilic bronchitis have improved symptoms of cough
or Leicester Cough Questionnaire scores.17,18
To date, there are no controlled, double-blind studies
looking at whether treating rhinosinusitis improves cough
symptoms in patients with chronic cough. There have been
a few open studies, which have looked at the outcome of
treating ‘PND’ on cough, following a diagnostic and treat-
ment algorithm, and these report a large degree of success
in controlling cough. For example, one study using oral first
generation antihistamine with a decongestant such as
pseudoephedrine reported success in 59% of patients pre-
senting with chronic cough and PND.4 However, in thesePre Post
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Figure 4 Endoscopic nasal scores (ENS) obtained by direct inspection of right and left nostril assessed before (pre) and after
(post) treatment of rhinosinusitis. There was a significant improvement in both nostrils following treatment.
1704 P. Macedo et al.studies, there was no report of symptom measurement or
examination of the rhinosinuses. It is also possible that
improvements observed may have been due to the central
effects of the orally administered drugs on the cough
reflex. There have been trials involving the use of topical
corticosteroids in allergic rhinitis, where improvements in
cough symptoms have been demonstrated,19 but these
patients did not present primarily with chronic cough as
a primary problem. The lack of correlation between
changes in rhinitis scores and changes in cough symptom
score indicate that the modest improvement in cough
symptom score may not have resulted from the effect of
the topical nasal treatments on rhinitis. It is possible that
the topical treatments had somehow acted on the airway
cough receptors.
When patients were recruited to this study, we found
that up to one third had never heard of the term ‘PND’,
although most knew about nasal catarrh or mucus in the
throat. This term is much more widely used and familiar in
the US.8 The large geographical variation in reported inci-
dence of PND is probably due to a combination of factors:
differing definitions of PND being used in different pop-
ulations, differing levels of awareness of the term and
perception of symptoms by different populations, and
a lack of a standardised method of measuring the symp-
toms. There has been a wide variation in the reported5 10 15 20
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Figure 5 Correlation between baseline cough scores and
Leicester cough questionnaire (LCQ) scores (rZ 0.75;
pZ 0.002).incidence of PND syndrome, with North American studies
reporting higher rates than European studies. For example,
in the United States, the reported incidence has ranged
from 26% to 87% of patients with chronic cough,4,20,21
whereas studies from the UK have reported rates varying
from 6% to 34%.11,22e26 The reason for the large differences
in reported incidence rates is unlikely to be explained
solely by the differences in the patient populations. There
is some evidence to suggest that patients attending clinics
in North America are more familiar with the term PND, and
are therefore more likely to report it as a symptom than
their UK counterparts.
Does ‘PND’ cause cough? This remains a contentious
issue between otolaryngologists and respiratory physi-
cians.27 Everyday, we produce around 20e40 mls of nasal
mucus9 which is expectorated or swallowed with saliva.
How a ‘postnasal drip’ may cause cough also remains
debatable. It has been postulated that mucoid secretions
may directly or indirectly (via inflammatory mediators)
stimulate pharyngeal or laryngeal cough receptors. Pratter
et al.4 have reported that approximately 20% of patients
with PND-associated with a chronic cough are not aware of
a postnasal drip sensation at the back of their throat.
Conversely, not all patients with ‘PND’ have cough. O’Hara
et al.9 found that out of 108 patients with purulent post-
nasal secretions attending a rhinology clinic, 21% com-
plained of cough, which still remains a sizeable proportion.
Because the PND syndrome is only defined according to
the presence of symptom(s), there have been moves to use
alternative labels for this condition. In their latest clinical
guidelines for the management of chronic cough, the
American College of Chest Physicians recommend using the
term upper airway cough syndrome (UACS), instead of PND
syndrome,7 to reflect fact that this is often associated with
upper airway abnormalities, such as extrathoracic airway
hypersensitivity.28 However, it is probably much simpler to
rename this as chronic cough associated with rhinosinusi-
tis8: this would be supported by our descriptive findings,
plus the response to specific therapy. The response of
cough to therapy was, however, small which questions
whether rhinosinusitis was entirely responsible for reported
cough in our patients. Cough may be related to laryngo-
pharyngeal reflux rather than to any postnasal problems.10
In a study by Gawchik et al.,19 patients with a history of
PND were enrolled into a double-blind study to receive
rabeprazole or placebo for 90 days. The aim of the study
Postnasal drip and cough 1705was to look at the relationship between extra-oesophageal
reflux and PND. Cough symptoms were evaluated as part of
a nine-item scale with reflux symptoms. Compared with
placebo, subjects receiving rabeprazole had a significant
reduction in PND frequency and cough symptoms. It is
unclear whether combination therapy of proton pump
inhibitor with therapies for rhinosinusitis would work
synergistically in reducing cough.
Although there are limitations to this ‘real-life’ study in
view of the absence of a control group, we tentatively
conclude that rhinosinusitis is present in many patients with
the PND syndrome and that topical treatment directed
towards rhinosinusitis may lead to improvement in associ-
ated chronic cough.
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